Natixis Advisors LLC Buys 3,800 Shares of Cencora, Inc. (NYSE:COR)

Natixis Advisors LLC raised its holdings in Cencora, Inc. (NYSE:COR) by 2.7% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 142,828 shares of the company’s stock after purchasing an additional 3,800 shares during the period. Natixis Advisors LLC’s holdings in Cencora were worth $32,091,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Hills Bank & Trust Co increased its holdings in Cencora by 3.7% in the 4th quarter. Hills Bank & Trust Co now owns 7,216 shares of the company’s stock valued at $1,621,000 after buying an additional 260 shares during the period. Aviso Financial Inc. increased its holdings in Cencora by 21.2% in the 4th quarter. Aviso Financial Inc. now owns 7,464 shares of the company’s stock valued at $1,677,000 after buying an additional 1,305 shares during the period. CFO4Life Group LLC increased its holdings in Cencora by 7.2% in the 4th quarter. CFO4Life Group LLC now owns 1,293 shares of the company’s stock valued at $291,000 after buying an additional 87 shares during the period. Skandinaviska Enskilda Banken AB publ increased its holdings in Cencora by 122.6% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 342,582 shares of the company’s stock valued at $76,982,000 after buying an additional 188,660 shares during the period. Finally, Achmea Investment Management B.V. increased its holdings in Cencora by 8.5% in the 4th quarter. Achmea Investment Management B.V. now owns 125,870 shares of the company’s stock valued at $28,281,000 after buying an additional 9,857 shares during the period. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Up 0.8 %

Shares of NYSE COR opened at $258.09 on Monday. The firm’s 50-day simple moving average is $247.59 and its 200 day simple moving average is $239.15. The company has a market cap of $50.05 billion, a price-to-earnings ratio of 36.71, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $263.70.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.85%. Cencora’s payout ratio is presently 31.29%.

Insider Buying and Selling at Cencora

In other Cencora news, CEO Robert P. Mauch sold 4,970 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the transaction, the chief executive officer now directly owns 51,070 shares in the company, valued at approximately $13,022,850. This represents a 8.87 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $260.06, for a total transaction of $520,120.00. Following the transaction, the chief accounting officer now owns 20,154 shares in the company, valued at approximately $5,241,249.24. The trade was a 9.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 13,648 shares of company stock worth $3,382,462. Company insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Evercore ISI upped their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. Mizuho assumed coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price on the stock. Wells Fargo & Company upped their target price on shares of Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a report on Friday. Finally, StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a report on Wednesday, March 12th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Cencora currently has an average rating of “Moderate Buy” and a consensus target price of $280.20.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.